Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, September 14, 2026 — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Nerviano Medical Sciences S.r.l. (“NMS”) today announced that they have reached a settlement and amended […]
Nerviano Medical Sciences and HiDiamond Biotechnology Enter Collaboration and License Agreement for NMS-173, a Potential Best-in-Class Covalent Dual mIDH1/2 Inhibitor
Nerviano Medical Sciences and HiDiamond Biotechnology Enter Collaboration and License Agreement for NMS-173, a Potential Best-in-Class Covalent Dual mIDH1/2 Inhibitor HiDiamond will advance the clinical development of NMS-173 in Phase 1/2, in collaboration with NMS through a Joint Development Committee (JDC). This framework combines NMS’s scientific and development expertise with HiDiamond’s clinical development capabilities to […]
Nerviano Medical Sciences announces participation at WCLC 2026 with a poster presentation
Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, to its participation in the upcoming World Conference on Lung Cancer (“WCLC”) of the International Association for the Study of Lung Cancer (“IASLC”), taking place in Seoul, Republic of Korea, from September 12 to 15, 2026. At the meeting, NMS will present a scientific poster […]
Nerviano Medical Sciences announces participation at EACR 2026 with poster presentations
Milan, Italy, 5 June 2026 – Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, is proud to announce its participation in the upcoming Annual Congress of the European Association for Cancer Research (EACR), taking place in Budapest, Hungary, from June 8 to 11, 2026. At the meeting, NMS will present a scientific poster featuring […]
Nerviano Medical Sciences announces participation at AACR 2026 with two poster presentations
Milan, Italy, 16 April 2026 – Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, is proud to announce its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. At the meeting, NMS will present two scientific posters highlighting its […]
Explore Nerviano Medical Sciences’ Latest ESMO TAT Posters
We are pleased to announce the availability of two Trial-in-Progress posters presented by Nerviano Medical Sciences at the ESMO TAT Congress 2026 held March 16–18, 2026, in Paris, France. These posters highlight ongoing clinical studies of Itareparib (NMS-03305293), our non-trapping, PARP1-selective inhibitor and the only third-generation inhibitor currently in clinical development. With strong brain and […]
Nerviano Medical Sciences at Bio-Europe Spring 2026
We are pleased to announce that Nerviano Medical Sciences will be attending BIO-Europe Spring 2026, in Lisbon, March 23–25, 2026. BIO-Europe is a premier partnering event for the global biotechnology industry, bringing together leading companies to foster collaboration and drive innovation. Our team looks forward to connecting with partners, exploring new opportunities, and discussing our […]
Nerviano Medical Sciences Announces Presentation of Two Trial-in-Progress Posters for Itareparib at ESMO TAT 2026
MILAN, Italy, March 16, 2026 – Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, today announced the presentation of two Trial-in-Progress posters featuring Itareparib (NMS-03305293) at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026, taking place March 16–18, 2026 in Paris, France. The presentations highlight ongoing clinical studies of Itareparib, NMS’s non-trapping, PARP1-specificinhibitor, […]
Nerviano Medical Sciences S.r.l. Announces Discontinuation of the Clinical Trial to Evaluate NMS-153 in combination with checkpoint inhibitor/cancer immunotherapy due to Lack of Efficacy in Immune Treatment Experienced Patients.
MILAN, Italy, 16 MARCH 2026 – Nerviano Medical Sciences S.r.l. (NMS), a global oncology-focused biopharmaceutical company today announced that it is discontinuing its Phase 2 clinical study1 of the investigational Monopolar Spindle 1 (MPS1) inhibitor NMS-153 for the treatment of immune-experienced hepatocellular cancer patients in combination with atezolizumab (Tecentriq®). The trial confirmed favorable safety profile, […]
Nerviano Medical Sciences announces NMPA Clearance of IND for PARP7-Selective Inhibitor Atamparib in Promising New Therapeutic Setting
NERVIANO, Italy, BOSTON, Mass., SHANGHAI, China, 12 January 2026 – NMS Group (NMS), a global leader in oncological innovation, today announced that the China’s National Medical Products Administration (NMPA) has granted approval to the Investigational New Drug (IND) application for its first-in-class, orally bioavailable PARP7-selective inhibitor, atamparib, enabling its clinical studies in patients with advanced solid […]